اعلان هااااااااااااااام


Translate

Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes (GSK - GlaxoSmithKline plc)

Monday, January 14, 2013

WN.com - Business News
Latest headlines from WN Network
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes (GSK - GlaxoSmithKline plc)
Jan 14th 2013, 10:47

(Source: GSK - GlaxoSmithKline plc) Issued: Monday 14 January 2013, London UK - LSE Announcement GlaxoSmithKline (GSK) plc today announced a regulatory submission to the US Food and Drug Administration (US FDA) for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes.  Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.   GSK intends to submit a regulatory application in the European Union (EU) in early 2013. About albiglutide Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly...
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes (GSK - GlaxoSmithKline plc)

Post a Comment